To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Phase 2 Completed 4 enrolled Incyte Corporation

Non-randomizedSequentialOpen-labelTreatment

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

Evaluation	Drug	Modality	Dose	Route
Subject	Itacitinib	Small molecule	—	Oral